Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
The funds raised will be used to advance Elkedonia's novel neuroplastogen approach to identify and optimize drug-like small molecule inhibitors of Elk1, a novel intracellular target previously considered to be "undruggable". Elk1 plays a pivotal role in reward brain circuits and neuroplasticity. These mechanisms are often altered in conditions like depression, Post-Traumatic Stress Disorder (PTSD), and addiction, making them chronic instead of transient. Preclinical and clinical studies suggest that Elk1 inhibition offers a promising and differentiated new approach to treating treatment-resistant depression, with rapid efficacy and without the side effects of psychedelics or ketamine derivatives, such as sedation, dependence, or hallucinations. Part of the financing will be directed toward biomarker research and validation efforts, supporting a precision-based therapeutic strategy.
This scientific and commercial potential was identified early by Argobio, which selected and developed Elkedonia within its venture studio. Founded in Paris and backed by leading investors including Angelini Ventures, Argobio partners with European academic institutions to transform early-stage discoveries into biotech companies, with a focus on rare diseases, neuroscience, oncology and immunology.Elkedonia is the first of these ventures to reach a significant financing milestone — a clear validation of Argobio's model and approach. This strong European investor syndicate reflects both the confidence of Argobio's founding investors in its model and Elkedonia's ability to attract leading life sciences investors at the seed stage. Building on this momentum, Argobio continues to expand its portfolio with the ambition to scale a repeatable model of biotech creation, driven by scientific excellence, entrepreneurial leadership and long-term investor alignment.
'We are excited to support Elkedonia's groundbreaking work in advancing neuroplastogens, which represents a potential first-in-class approach to treating depression,' said Fabrizio Calisti, Medical Director at Angelini Ventures. 'The novel nature of Elkedonia's target Elk1, previously thought to be undruggable, sets the company apart in the landscape of depression treatments, and we are proud to be part of this transformative journey. This investment reflects Angelini Ventures' commitment to supporting the exciting science coming out of European academic laboratories at the earliest stages via Argobio and subsequently providing further capital through our venture fund to accelerate the translation of cutting-edge research into therapies with the potential to transform outcomes for people with neuropsychiatric disorders.'
Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Elkedonia's Board of Directors.
'I am thrilled to welcome our founding seed investors and thank my colleagues at Argobio for their support in creating Elkedonia. The novelty of our neuroplastogen approach offers a strong value proposition supported by groundbreaking neuroscience research. We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly,' said Delphine Charvin, Chief Executive Officer and Co-Founder of Elkedonia, previously Operating Partner at Argobio. 'In addition, our development of biomarkers will allow us to pursue a precision medicine for patient selection and treatment efficacy monitoring.'
***
Notes to EditorsAbout Angelini Ventures
Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies.
To date, Angelini Ventures has invested around €100 million into 21 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. www.angeliniventures.com
About Angelini Industries
Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over two billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates.www.angeliniindustries.com
About Elkedonia Elkedonia is a Franco-Belgian start-up company dedicated to transforming the treatment of mental health disorders. Elkedonia is introducing a first-in-class antidepressant approach that leverages precision medicine. The lead discovery program targets the inhibition of the intracellular Elk1 protein to address the needs of treatment-resistant depression (TRD).www.elkedonia.com
About ArgobioArgobio is an international biotech start-up studio committed to turning cutting-edge innovations into breakthrough biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Seed or Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development.www.argobiostudio.com
ContactsAngelini VenturesMartina Palmese, Communications Coordinatormartina.palmese@angeliniventures.com
Media contacts for Italy - SEC Newgate ItaliaDaniele Pinosa, daniele.pinosa@secnewgate.it; Tel. +39 3357233872Fausta Tagliarini; fausta.tagliarini@secnewgate.it; Tel. +39 3476474513Daniele Murgia; daniele.murgia@secnewgate.it; Tel. +39 3384330031
Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallowangeliniventures@medistrava.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
14 minutes ago
- Bloomberg
Advent Seeks to Buy Swiss Chipmaker U-blox in $1.3 Billion Deal
Advent International offered to buy U-blox Holding AG, a Swiss maker of positioning chips, in a deal valued at about 1.05 billion Swiss francs ($1.3 billion). Advent's cash offer of 135 Swiss francs per share, while representing a 53% premium over volume-weighted averages of the last six months, is less than U-blox's closing price of 138.60 Swiss francs on Friday.
Bloomberg
an hour ago
- Bloomberg
CEO Pay at FTSE 100 Firms Hit a Record High, Study Says
Annual pay for bosses of FTSE 100 companies hit a record high for the third consecutive year. The median pay for chief executive officers at the 100 biggest companies traded on the London Stock Exchange reached £4.6 million ($6.2 million), according to research from think tank High Pay Centre.
Motor 1
2 hours ago
- Motor 1
Volkswagen Is Locking Horsepower Behind a Paywall
Automakers are embracing subscriptions whether customers like them or not, often pushing beyond what most of us find acceptable. BMW attempted to charge a monthly fee for heated seats, but users didn't bite . On the opposite end of the spectrum, Mercedes-Benz still offers Acceleration Increase for its EQ models, which initially cost $1,200 a year, and it's an idea that Volkswagen is borrowing for the electric ID.3 in the United Kingdom. Auto Express first reported that the automaker's consumer site in the UK market lists the ID.3 Pro and Pro S as only having 201 horsepower instead of the full 228-hp output. The fine print reads that owners can "activate the optional power upgrade for a fee." VW offers owners the option of a one-month free trial, a monthly or yearly subscription, or the ability to purchase it for the car's lifetime. Those costs are: £16.50 per month, £165 per year, or £649 outright, which is $22.36, $211.41, and $879,52, respectively, at today's exchange rate. It's an odd decision and one that doesn't make much financial sense for a buyer on a car that costs around $50,000 to start. The extra cost is small enough to be hidden in the MSRP, and something most people would likely be willing to pay upfront. But this paywall feels like an unnecessary hurdle designed to nickel-and-dime customers who might be leasing rather than buying. Automotive News Europe reported in late 2023 that more than 40 percent of new lease registrations in the UK were electric vehicles, so someone who only keeps the car for a few years might be able to save a few hundred dollars. Volkswagen ID.3 Interior It doesn't seem worth it, and thankfully VW isn't doing that in America, but it reveals where the industry stands and what it's thinking. Automakers are seeking new revenue streams during a complex and costly time in the industry, and a recurring income from thousands or millions of drivers is enticing. You'd think spending tens of thousands of dollars would guarantee you can purchase and fully own a complete vehicle, but that's no longer the case when software sits between the user and the actual hardware. Software licenses and end-user license agreements restrict ownership while the Digital Millennium Copyright Act dictates what a user can and cannot do with that license. In 2023, Mazda sent a cease-and-desist letter to a developer who had made integrations that connected Mazda vehicles to Home Assistant, an open-source home automation software. The automaker accused the developer of writing code that infringed on its 'copyright ownership,' which provided similar functionality to that offered by Mazda through its apps. While the DMCA allows owners to modify what they own, it's illegal to distribute the software or tools to do it, especially if it violates copyright, and today's cars are packed with copyrighted software. American automakers are already making the argument in court that customers don't fully own the vehicles they paid for, pointing to software and software licenses in their attempt to restrict right-to-repair laws. As automakers embed more software into cars, EVs or ICE, it will make paywalling horsepower, safety features, or access to other hardware features even easier because you can't own someone else's copyrighted code, and VW's UK experiment should be a red alert for car buyers everywhere. Too Many Subscriptions: The New Audi A3 Is Amess With In-Car Subscriptions [Update] Mazda Now Requires Monthly Subscription for Remote Start Stay informed with our newsletter every weekday back Sign up For more information, read our Privacy Policy and Terms of Use . Sources: Auto Express , Automotive News , Ars Technica , Volkswagen UK Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
